Category: Uncategorized

CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION

Written by Sam Nelson on March 1, 2021

Berkeley Heights, NJ — March 1, 2021 — CorMedix Inc….

CORMEDIX INC. TO BEGIN TRADING ON THE NASDAQ STOCK EXCHANGE

Written by Sam Nelson on January 21, 2021

Berkeley Heights, NJ – January 21, 2021 – CorMedix Inc. (NYSE…

CORMEDIX INC. ANNOUNCES FDA DECISION THAT ADVISORY COMMITTEE MEETING FOR NEW DRUG APPLICATION FOR DEFENCATH IS NOT NEEDED

Written by Sam Nelson on November 18, 2020

PDUFA date remains February 28, 2021 Potentially the first antibacterial…

CORMEDIX INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on November 5, 2020

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CorMedix Appoints Greg Duncan to its Board of Directors

Written by Sam Nelson on November 2, 2020

Seasoned industry veteran with decades of strategic and commercial leadership…

CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5

Written by Sam Nelson on October 29, 2020

Berkeley Heights, NJ – October 29, 2020 – CorMedix Inc. (NYSE…

CorMedix to Participate in BIO Investor Forum Digital

Written by Sam Nelson on October 8, 2020

Berkeley Heights, NJ – October 8, 2020 – CorMedix Inc. (NYSE…

Cormedix Appoints Paulo Costa to its Board of Directors

Written by Sam Nelson on September 17, 2020

Seasoned industry veteran with decades of strategic and commercial leadership…

CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Written by Sam Nelson on September 9, 2020

Berkeley Heights, NJ – September 9, 2020 – CorMedix Inc. (NYSE…

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DEFENCATH

Written by Sam Nelson on August 31, 2020

FDA sets PDUFA goal date of February 28, 2021 Potentially…

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on August 10, 2020

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10

Written by Sam Nelson on August 4, 2020

Berkeley Heights, NJ – August 3, 2020 – CorMedix Inc. (NYSE…

CorMedix Announces Pricing of $20M Public Offering of Common Stock

Written by Sam Nelson on July 28, 2020

Berkeley Heights, NJ – July 28, 2020 – CorMedix Inc….

CorMedix Announces Proposed Public Offering of Common Stock

Written by Sam Nelson on July 27, 2020

Berkeley Heights, NJ – July 27, 2020 – CorMedix Inc….

CORMEDIX INC. REPORTS SUBMISSION OF DEFENCATH™ NEW DRUG APPLICATION

Written by Sam Nelson on July 8, 2020

Priority Review of NDA Requested Berkeley Heights, NJ – July…

CORMEDIX INC. REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on May 11, 2020

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

Written by Sam Nelson on May 11, 2020

Berkeley Heights, NJ – May 11, 2020 – CorMedix Inc….

CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®

Written by Sam Nelson on May 6, 2020

Tuesday, May 19th @ 12pm Eastern Time  Berkeley Heights, NJ…

CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program

Written by Sam Nelson on April 22, 2020

Berkeley Heights, NJ – April 22, 2020 – CorMedix Inc….

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on March 17, 2020

Company in process of submitting New Drug Application (NDA) for…